Search

Your search keyword '"Carroll, Miles W"' showing total 597 results

Search Constraints

Start Over You searched for: Author "Carroll, Miles W" Remove constraint Author: "Carroll, Miles W"
597 results on '"Carroll, Miles W"'

Search Results

1. Serological analysis in humans in Malaysian Borneo suggests prior exposure to H5 avian influenza near migratory shorebird habitats

3. The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection

4. Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents

5. Influence of Landscape Patterns on Exposure to Lassa Fever Virus, Guinea

7. Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform

8. Divergent trajectories of antiviral memory after SARS-CoV-2 infection

9. Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial

10. Nipah Virus Therapeutics: A Systematic Review to Support Prioritisation for Clinical Trials

11. Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks

12. Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study

13. Virus genomes reveal factors that spread and sustained the Ebola epidemic

14. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

15. Human Diversity of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen Class I Alleles and Ebola Virus Disease Outcomes

16. Rvsv-Zebov Vaccination in People with Pre-Existing Immunity to Ebolavirus: An Open-Label Safety and Immunogenicity Study in Guinean Communities Affected by Ebola Virus Disease (L’Essai Proches)

17. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

19. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19

20. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19

21. ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

23. Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity

24. Animal models for COVID-19

25. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

26. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

31. Ebola Virus Persistence in Breast Milk After No Reported Illness: A Likely Source of Virus Transmission From Mother to Child

32. Gonadal androgens are associated with decreased type I interferon production by pDCs and increased IgG titres to BNT162b2 following co-vaccination with live attenuated influenza vaccine in adolescents

34. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

35. Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study

37. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction

39. Immunogenicity of a DNA vaccine candidate for COVID-19

44. Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days

45. Analysis of Diagnostic Findings From the European Mobile Laboratory in Guéckédou, Guinea, March 2014 Through March 2015

47. Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

49. Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine

Catalog

Books, media, physical & digital resources